Virios Therapeutics, Inc. (NASDAQ:VIRI) Director William Pridgen Acquires 13,450 Shares

Virios Therapeutics, Inc. (NASDAQ:VIRIGet Rating) Director William Pridgen purchased 13,450 shares of the company’s stock in a transaction on Tuesday, May 17th. The stock was acquired at an average price of $4.38 per share, with a total value of $58,911.00. Following the completion of the purchase, the director now directly owns 36,469 shares in the company, valued at $159,734.22. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

William Pridgen also recently made the following trade(s):

  • On Tuesday, March 29th, William Pridgen acquired 600 shares of Virios Therapeutics stock. The shares were bought at an average cost of $4.94 per share, for a total transaction of $2,964.00.
  • On Wednesday, March 23rd, William Pridgen purchased 2,197 shares of Virios Therapeutics stock. The shares were bought at an average price of $5.46 per share, with a total value of $11,995.62.

NASDAQ:VIRI opened at $4.57 on Thursday. The stock’s fifty day moving average is $4.46 and its two-hundred day moving average is $5.24. Virios Therapeutics, Inc. has a 52 week low of $3.30 and a 52 week high of $7.45.

Virios Therapeutics (NASDAQ:VIRIGet Rating) last issued its earnings results on Thursday, March 17th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.02). During the same quarter in the previous year, the business posted ($1.25) earnings per share. On average, research analysts predict that Virios Therapeutics, Inc. will post -2.19 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the business. UBS Group AG increased its stake in Virios Therapeutics by 528.3% in the 1st quarter. UBS Group AG now owns 14,137 shares of the company’s stock valued at $63,000 after buying an additional 11,887 shares during the last quarter. Vanguard Group Inc. boosted its position in Virios Therapeutics by 63.4% during the first quarter. Vanguard Group Inc. now owns 241,666 shares of the company’s stock worth $1,082,000 after purchasing an additional 93,800 shares during the period. Cetera Advisors LLC raised its stake in Virios Therapeutics by 22.0% in the first quarter. Cetera Advisors LLC now owns 43,944 shares of the company’s stock valued at $197,000 after purchasing an additional 7,934 shares in the last quarter. BlackRock Inc. boosted its holdings in Virios Therapeutics by 17.6% in the fourth quarter. BlackRock Inc. now owns 18,641 shares of the company’s stock valued at $95,000 after acquiring an additional 2,785 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Virios Therapeutics by 10.5% in the 4th quarter. Geode Capital Management LLC now owns 22,564 shares of the company’s stock worth $115,000 after purchasing an additional 2,135 shares during the last quarter. 11.40% of the stock is currently owned by hedge funds and other institutional investors.

Virios Therapeutics Company Profile (Get Rating)

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.

Further Reading

Insider Buying and Selling by Quarter for Virios Therapeutics (NASDAQ:VIRI)

Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.